TNFRSF11B and hypertensive disorder: Nevertheless, these data indicate that decreased BRS could be a physiological marker of CV risk in T2D patients on oral antidiabetic drugs, OPG could be a major contributor to the decreased BRS in these patients, and TNF-α might be a potential determinant of decline in BRS in T2D patients with hypertension receiving oral antidiabetic and antihypertensive drugs.